PROTACEGFRdegrader 15 is a bifunctional EGFR PROTAC degrader composed of Pomalidomide and Gefitinib. It facilitates EGFR degradation through ubiquitin-proteasome dependent proteolysis and autophagic-lysosomal pathways. Additionally, PROTACEGFRdegrader 15 targets ETFA to enhance ATP production. It significantly suppresses tumor growth in Gefitinib-resistant HCC-827 xenograft models.

YHV98-4 is a selective Hv1 channel (Hv1 channel) inhibitor that can cross the blood-brain barrier. It specifically inhibits the Hv1 channel with a half-maximal inhibitory concentration of 1 µM without affecting other ion channels. YHV98-4 decreases the spread of p-tau, enhances ATP production, and promotes microglial mitophagy. By inhibiting the Hv1 channel and reducing ROS production, it alleviates inflammatory pain. Additionally, YHV98-4 enhances the transfer of mitochondria (mitochondria) from microglia to neurons, aiding in the delivery of functional mitochondria, thereby repairing neuronal damage and improving cognitive function. It mitigates inflammation and is applicable in Alzheimer’s disease research.

PRP020 is a potent and specific inhibitor of mycobacterial ATP synthase, which does not inhibit succinate-driven acidification. It exhibits a MIC95 of 2 μM against M. tuberculosis and remains effective against most resistant mutant strains. PRP020 is highly safe and suitable for use in tuberculosis research.